Noninvasive PETCT Imaging Using 68Ga-XACP3 Compared to 68Ga-PSMA in Adults With Prostate Cancer

What this Trial Is About

Researchers are evaluating a new imaging approach using 68Ga-XACP3 PETCT to detect tumor lesions in men with prostate cancer. This study compares the diagnostic performance of 68Ga-XACP3 PETCT with the current standard imaging method, 68Ga-PSMA PETCT, aiming to improve detection of initial or recurrent prostate cancer lesions. The study is led by The First Affiliated Hospital of Xiamen University. Participants receive a single intravenous injection of both 68Ga-XACP3 and 68Ga-PSMA radiotracers, followed by PETCT imaging within a designated time frame. The study records tumor uptake using maximum standard uptake value SUVmax and counts the number of positive tumor lesions detected by both imaging methods. Diagnostic accuracy of 68Ga-XACP3 will be calculated and compared to 68Ga-PSMA. During the study, participants undergo both PETCT scans and clinical assessments to evaluate tumor detection. Researchers will measure diagnostic efficacy over one year, focusing on the number of lesions identified and SUV values. Participants must provide informed consent, and safety and imaging results will be monitored throughout the study period, which runs until October 2027.

68Ga-XACP3 PET/CT in Prostate Cancer